{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:25:03Z","timestamp":1788218703441,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.urolonc.2022.12.008","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T05:15:40Z","timestamp":1673932540000},"page":"148.e17-148.e24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8877-6799","authenticated-orcid":false,"given":"Thomas","family":"Gerald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaly","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bagrodia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Greg","family":"Call","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Mauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon L.","family":"Woldu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2022.12.008_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.urolonc.2022.12.008_bib0002","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10552-020-01366-1","article-title":"Bladder cancer stage and mortality: urban vs. rural residency","volume":"32","author":"Deuker","year":"2021","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.urolonc.2022.12.008_bib0003","unstructured":"Network NCC. Bladder cancer (version 2.2022). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf. Published 2022. Accessed June 1, 2022."},{"issue":"7","key":"10.1016\/j.urolonc.2022.12.008_bib0004","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.12.008_bib0005","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"issue":"17","key":"10.1016\/j.urolonc.2022.12.008_bib0006","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"17","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2022.12.008_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103683","article-title":"Recent therapeutic advances in urothelial carcinoma: a paradigm shift in disease management","volume":"174","author":"Bellmunt","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"24","key":"10.1016\/j.urolonc.2022.12.008_bib0008","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.18632\/oncotarget.26797","article-title":"Clinical validation of the tempus xT next-generation targetedoncology sequencing assay","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.urolonc.2022.12.008_bib0009","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41587-019-0259-z","article-title":"Integrated genomic profiling expands clinical options for patients with cancer","volume":"37","author":"Beaubier","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.urolonc.2022.12.008_bib0010","unstructured":"Agilent technologies I. PD-L1 IHC 22C3 pharmDx interpretation manual - urothelial carcinoma. https:\/\/www.agilent.com\/cs\/library\/usermanuals\/public\/29276_22C3_pharmdx_uc_interpretation_manual_us.pdf. Published 2021. Accessed 12\/16\/2022."},{"key":"10.1016\/j.urolonc.2022.12.008_bib0011","unstructured":"Roche Diagnostics NA. Ventana PD-L1 (SP142) assay. https:\/\/diagnostics.roche.com\/us\/en\/products\/tests\/ventana-pd-l1-_sp142-assay1.html. Published 2022. Accessed 12\/16\/2022."},{"key":"10.1016\/j.urolonc.2022.12.008_bib0012","unstructured":"Agilent technologies I. PD-L1 IHC 28-8 pharmDx interpretation manual - urothelial carcinoma. https:\/\/www.agilent.com\/cs\/library\/usermanuals\/public\/29458-d69027-pd-l1-ihc-28-8_uc_interpretation%20manual_en-us.pdf. Published 2021. Accessed 12\/16\/2022."},{"issue":"6","key":"10.1016\/j.urolonc.2022.12.008_bib0013","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2022.12.008_bib0014","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1093\/annonc\/mdx405","article-title":"Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance","volume":"28","author":"Barata","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.12.008_bib0015","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/bju.14370","article-title":"Germline mutations in DNA repair genes are associated with bladder cancer risk and unfavourable prognosis","volume":"122","author":"Na","year":"2018","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2022.12.008_bib0016","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.12.008_bib0017","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2022.12.008_bib0018","unstructured":"Administration USFaD. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors. Published 2020. Accessed 05\/23\/2022, 2022."},{"issue":"9","key":"10.1016\/j.urolonc.2022.12.008_bib0019","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.annonc.2020.07.002","article-title":"The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) >\/=10: a decision centered on empowering patients and their physicians","volume":"31","author":"Subbiah","year":"2020","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2022.12.008_bib0020","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 keynote-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7693","key":"10.1016\/j.urolonc.2022.12.008_bib0021","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"10064","key":"10.1016\/j.urolonc.2022.12.008_bib0022","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.urolonc.2022.12.008_bib0023","doi-asserted-by":"crossref","first-page":"v296","DOI":"10.1093\/annonc\/mdx371.003","article-title":"Impact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study","volume":"28","author":"Galsky","year":"2017","journal-title":"Ann Oncol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2022.12.008_bib0024","article-title":"Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study","volume":"36","author":"Powles","year":"2018","journal-title":"Jf Clin Oncol"},{"key":"10.1016\/j.urolonc.2022.12.008_bib0025","article-title":"Role of immunotherapy in bladder cancer","volume":"26","author":"Rhea","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.urolonc.2022.12.008_bib0026","unstructured":"Administration USFaD. FDA limits the use of Tecentriq and Keytruda for some urothelial cancer patients. Published 2018. Accessed 06\/01\/2022, 2022."},{"key":"10.1016\/j.urolonc.2022.12.008_bib0027","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2147\/OTT.S165840","article-title":"Bacillus calmette-guerin and anti-PD-L1 combination therapy boosts immune response against bladder cancer","volume":"11","author":"Wang","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"11","key":"10.1016\/j.urolonc.2022.12.008_bib0028","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1007\/s00345-020-03329-2","article-title":"PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment","volume":"39","author":"Roumiguie","year":"2021","journal-title":"World J Urol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2022.12.008_bib0029","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1200\/JCO.2022.40.6_suppl.545","article-title":"PD-L1 expression and BCG response in nonmuscle invasive bladder cancer","volume":"40","author":"Woldu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2022.12.008_bib0030","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"Keynote-676: phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC","volume":"16","author":"Kamat","year":"2020","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.12.008_bib0031","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.hoc.2014.11.003","article-title":"Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer","volume":"29","author":"McConkey","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"10.1016\/j.urolonc.2022.12.008_bib0032","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1158\/1541-7786.MCR-10-0168","article-title":"Roles of fibroblast growth factor receptors in carcinogenesis","volume":"8","author":"Haugsten","year":"2010","journal-title":"Mol Cancer Res"},{"issue":"5","key":"10.1016\/j.urolonc.2022.12.008_bib0033","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.eururo.2019.06.025","article-title":"Fibroblast growth factor receptor 3 alterations and response to PD-1\/PD-L1 blockade in patients with metastatic urothelial cancer","volume":"76","author":"Wang","year":"2019","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2022.12.008_bib0034","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41416-021-01488-6","article-title":"Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience","volume":"125","author":"Rose","year":"2021","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2022.12.008_bib0035","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.urolonc.2022.12.008_bib0036","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.eururo.2022.02.028","article-title":"Prognostic and predictive value of fibroblast growth factor receptor alterations in high-grade non-muscle-invasive bladder cancer treated with and without bacillus calmette-guerin immunotherapy","volume":"81","author":"Mayr","year":"2022","journal-title":"Eur Urol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2022.12.008_bib0037","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS603","article-title":"A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Gu\u00e9rin (BCG) therapy","volume":"38","author":"Steinberg","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.12.008_bib0038","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/MOU.0000000000000776","article-title":"Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer","volume":"30","author":"Bronimann","year":"2020","journal-title":"Curr Opin Urol"},{"issue":"13","key":"10.1016\/j.urolonc.2022.12.008_bib0039","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-20-5037","article-title":"Detection of molecular signatures of homologous recombination deficiency in bladder cancer","volume":"27","author":"Borcsok","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.urolonc.2022.12.008_bib0040","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2022.12.008_bib0041","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","article-title":"Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma","volume":"2","author":"Liu","year":"2016","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2022.12.008_bib0042","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2022.12.008_bib0043","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1200\/JCO.2021.39.6_suppl.397","article-title":"A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (retain bladder): interim analysis","volume":"39","author":"Geynisman","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922004938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922004938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T07:50:23Z","timestamp":1741593023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922004938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1078143922004938"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.12.008","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}